Overview of Dr. Jurcic
I am currently Professor of Medicine at Columbia University Medical Center and Director of the Hematologic Malignancies Section of the Division of Hematology/Oncology. Prior to joining the faculty at Columbia University Medical Center in January, 2013, I was an Attending Physician on the Leukemia Service at Memorial Sloan-Kettering Cancer Center for over 18 years. My main focus is the treatment of acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome. My research interests include acute myeloid leukemia, radioimmunotherapy with alpha and beta particle-emitting radioisotopes, monoclonal antibody-based therapies for leukemia, the development of novel small molecule inhibitors for leukemia, and the molecular monitoring of minimal residual disease. I am the 2001 recipient of the Louis and Allston Boyer Young Investigator Award for Distinguished Achievement in Biomedical Research from Memorial Sloan-Kettering Cancer Center. I am author or coauthor of more than 90 articles and book chapters, have been the principal investigator on over 40 clinical trials, and regularly lecture at national and international meetings. I served as a Leukemia Section Editor for The Oncologist from 2007-2015.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1991 - 1994
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1988 - 1991
Perelman School of Medicine at the University of PennsylvaniaClass of 1988
University of PittsburghBS, Mathematics & Philosophy, Summa cum laude, 1979 - 1984
Certifications & Licensure
Awards, Honors, & Recognition
- New York Magazine: Top Doctors Castle Connolly, 2014-2020
- America's Top Doctors Castle Connolly, 2010-2020
- Top Doctors: New York Metro Area Castle Connolly, 2007-2020
- Join now to see all
Clinical Trials
Publications & Presentations
PubMed
- 1 citations
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
Keith W Pratz, Mohamad Cherry, Jessica K Altman, Brenda W Cooper, Nikolai A Podoltsev, Jose Carlos Cruz, Tara L Lin, Gary J Schiller, Joseph G Jurcic, Adam Asch, Ruish...> ;Journal of Clinical Oncology. 2023 Sep 10 Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS).
Abdullah Mahmood Ali, Fatima BenMohamed, Alessandra Decina, Sanjay Mukherjee, Shelley Levi, Laura Nalleli Garrido Castillo, Davide Bréchot, Joseph Jurcic, Azra Raza, P...> ;Medical Oncology. 2023 Jun 14- 3 citations
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies.
Prabhjot S Mundi, Filemon S Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R Rainey, Kristina Guillan, Armaan Siddiquee, Daoqi You, Ronald Realubit, ...> ;Cancer Discovery. 2023 Jun 2 - Join now to see all
Books/Book Chapters
Clinical Radiation Oncology
Chapter: Targeted radionuclide therapy
Jurcic JG, Wong JYC, Knox SJ, Wahl D, Rosenblat T, Meredith RFEditors: Gunderson LL, Tepper JL.Elsevier, Inc., PhiladelphiaEdition 4,2015Hematological Malignancies in Children, Adolescents and Young Adults
Chapter: Childhood, adolescent and young adult acute myeloid leukemias
Page 265 - 312Arceci RJ, Meshinchi S, Rosenblat TL, Jurcic JG, Tallman MSEditors: Cairo MS, Perkins SL.World Scientific Publishing Co., Inc., Singapore2012Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer
Chapter: Radioimmunotherapy of acute myeloid leukemia
Page 219 - 240Rosenblat TL, Jurcic JGEditors: Reilly R.John Wiley & Sons, Inc, Hoboken2010- Join now to see all
Abstracts/Posters
Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience
Joseph G. Jurcic, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Na¥ve Patients with Higher-Risk Myelodysplastic Syndrome
Joseph G. Jurcic, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Tr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018Alpha Particle Therapy of Hematologic Malignanices
26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain - 11/2014- Join now to see all
Press Mentions
Actinium Pharmaceuticals Unveils New Clinical Trial for Leukemia with Its Treatment Actimab-AJune 28th, 2018
Actinium (NYSE: $ATNM) Announces Initiation of Phase 2 Clinical Trial of Actimab-A in Patients Newly Diagnosed with Acute Myeloid Leukemia over Age 60September 27th, 2016
Actinium KOL Joseph Jurcic, MD to Discuss the Role of Actinium’s Alpha-Particle Radiopharmaceuticals in the Treatment of Leukemia Patients at the 2014 Society of Nuclear Medicine and Molecular Imaging Annual MeetingJune 5th, 2014
- Join now to see all
Committees
- Member, Education Committee, Society of Hematologic Oncology 2013 - Present
- Member, Southwest Oncology Group, Leukemia Committee and Leukemia Committee Working Group 2013 - Present
- Member, Scientific Program Committee on Leukemia, Myelodysplasia, and Transplantation, American Society of Clinical Oncology 2014 - 2016
Professional Memberships
Hospital Affiliations
Insurance Accepted
Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPOHumana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO- Please verify your coverage with the provider's office directly when scheduling an appointment
